JP2008501758A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501758A5
JP2008501758A5 JP2007526300A JP2007526300A JP2008501758A5 JP 2008501758 A5 JP2008501758 A5 JP 2008501758A5 JP 2007526300 A JP2007526300 A JP 2007526300A JP 2007526300 A JP2007526300 A JP 2007526300A JP 2008501758 A5 JP2008501758 A5 JP 2008501758A5
Authority
JP
Japan
Prior art keywords
disorder
depression
disorders
onset
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007526300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501758A (ja
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed filed Critical
Priority claimed from PCT/EP2005/006182 external-priority patent/WO2005121140A1/en
Publication of JP2008501758A publication Critical patent/JP2008501758A/ja
Publication of JP2008501758A5 publication Critical patent/JP2008501758A5/ja
Withdrawn legal-status Critical Current

Links

JP2007526300A 2004-06-09 2005-06-07 ピロロピリジン誘導体 Withdrawn JP2008501758A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds
PCT/EP2005/006182 WO2005121140A1 (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Publications (2)

Publication Number Publication Date
JP2008501758A JP2008501758A (ja) 2008-01-24
JP2008501758A5 true JP2008501758A5 (enExample) 2008-03-27

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526300A Withdrawn JP2008501758A (ja) 2004-06-09 2005-06-07 ピロロピリジン誘導体

Country Status (25)

Country Link
US (1) US7589206B2 (enExample)
EP (1) EP1753764B1 (enExample)
JP (1) JP2008501758A (enExample)
KR (1) KR20070034049A (enExample)
AR (1) AR050158A1 (enExample)
AT (1) ATE412651T1 (enExample)
AU (1) AU2005251913A1 (enExample)
BR (1) BRPI0511874A (enExample)
CA (1) CA2569887A1 (enExample)
DE (1) DE602005010698D1 (enExample)
DK (1) DK1753764T3 (enExample)
ES (1) ES2317244T3 (enExample)
HR (1) HRP20090034T3 (enExample)
IL (1) IL179603A0 (enExample)
MA (1) MA28686B1 (enExample)
MX (1) MXPA06014471A (enExample)
NO (1) NO20070067L (enExample)
PE (1) PE20060430A1 (enExample)
PL (1) PL1753764T3 (enExample)
PT (1) PT1753764E (enExample)
RU (1) RU2006147278A (enExample)
SI (1) SI1753764T1 (enExample)
TW (1) TW200611695A (enExample)
UY (1) UY28945A1 (enExample)
WO (1) WO2005121140A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2005121140A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
ATE527258T1 (de) † 2004-07-28 2011-10-15 Takeda Pharmaceutical Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
MX2008001935A (es) * 2005-08-09 2008-03-26 Glaxo Group Ltd Derivados de imidazopiridina como ligandos del receptor de canabinoides.
WO2007118041A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
ES2389958T3 (es) * 2007-03-21 2012-11-05 Glaxo Group Limited Uso de derivados de quinolina en el tratamiento del dolor
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JPWO2010113834A1 (ja) 2009-03-30 2012-10-11 アステラス製薬株式会社 ピリミジン化合物
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PT2599774T (pt) * 2010-07-29 2016-09-23 Astellas Pharma Inc Compostos de piridina condensados como ligandos do recetor canabinoide cb2
WO2013140342A1 (en) * 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
NZ754039A (en) 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2020112937A1 (en) * 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (en) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
FI922347A0 (fi) 1990-01-05 1992-05-22 Pfizer Azaoxindolderivat.
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
DE69502587T2 (de) 1994-02-18 1998-11-26 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn. 2-heteroaryl-5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e] [1,4]diazepine und ihre verwendung zur vorbeugung und behandlung von hiv-infektion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0931872B1 (de) 1998-01-23 2003-04-09 Voith Paper Patent GmbH Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002523455A (ja) 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
WO2000053178A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
WO2000053180A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3396000A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2367116A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
NZ521978A (en) 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
IL152477A0 (en) 2000-04-28 2003-05-29 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
ES2262674T3 (es) 2000-08-14 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU8873101A (en) 2000-09-06 2002-03-22 Ortho Mcneil Pharm Inc A method for treating allergies using substituted pyrazoles
EP1315741A2 (en) 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6958358B2 (en) 2001-01-17 2005-10-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
SK287900B6 (sk) 2001-02-02 2012-03-02 Bristol-Myers Squibb Company Substituted azaindolexoacetic piperazine derivatives and pharmaceutical composition containing thereof
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
CZ20033053A3 (en) 2001-05-14 2004-05-12 Bristol@Myersásquibbápharmaácompany Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
ES2278064T3 (es) 2001-10-19 2007-08-01 Transtech Pharma Inc. Derivados de beta-carbolina como inhibidores de ptp.
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003080608A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
WO2004018434A1 (en) 2002-08-21 2004-03-04 Glaxo Group Limited Pyrimidine compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EA200500584A1 (ru) 2002-09-30 2006-02-24 Дженелэбс Текнолоджиз, Инк. Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
MXPA05008441A (es) 2003-02-14 2005-10-19 Wyeth Corp Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005121140A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives

Similar Documents

Publication Publication Date Title
JP2008501758A5 (enExample)
JP2007520539A5 (enExample)
JP2003511434A (ja) モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体
JP2020023528A (ja) ヒストンデアセチラーゼ阻害剤
CN110914262B (zh) κ阿片受体拮抗剂以及与其相关的产品和方法
ES2307861T3 (es) Derivados de 4-fenilpiperidina como moduladores de la neurotransmision de dopamina.
WO1999037623A3 (en) Sulphonamide derivatives for treatment of cns disorders
JP2008512402A (ja) 置換されたアニリン誘導体
EA012589B1 (ru) Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний
EA004860B1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
ATE203023T1 (de) Tropanderivate, deren herstellung und verwendung
JP2010523651A (ja) 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体
WO2014030716A1 (ja) ピラゾロピリミジン化合物
JP2007523206A5 (enExample)
JP2007504229A5 (enExample)
CN101203216A (zh) 二氢苯并呋喃衍生物及其用途
JP2008506765A (ja) １，３−置換シクロアミノ誘導体及びヒスタミン−３受容体拮抗剤としてのそれらの使用
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
KR20080103043A (ko) 우울증 환자에게 있는 수면 장애의 치료를 위해 의도된 치료제를 수득하기 위한 아고멜라틴의 사용
JPS61260063A (ja) フエニルアルカノ−ル誘導体
JP2012521974A (ja) キナゾリンジオン誘導体の治療での使用
JP2011500694A5 (enExample)
JP2016539157A (ja) ベンゾイミダゾール−プロリン誘導体の使用
JP2005508872A5 (enExample)
US7671056B2 (en) Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor